share_log

JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45

JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45

JMP证券维持Protagonist Therapeutics的市场跑赢大盘,将目标股价上调至45美元
Benzinga ·  05/08 14:09

JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $42 to $45.

JMP证券分析师乔纳森·沃勒本维持Protagonist Therapeutics(纳斯达克股票代码:PTGX)的市场表现跑赢大盘,并将目标股价从42美元上调至45美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发